Solid lipid nanoparticles as nucleic acid delivery system: properties and molecular mechanisms
- PMID: 25578828
- DOI: 10.1016/j.jconrel.2015.01.010
Solid lipid nanoparticles as nucleic acid delivery system: properties and molecular mechanisms
Abstract
Solid lipid nanoparticles (SLNs) have been proposed in the 1990s as appropriate drug delivery systems, and ever since they have been applied in a wide variety of cosmetic and pharmaceutical applications. In addition, SLNs are considered suitable alternatives as carriers in gene delivery. Although important advances have been made in this particular field, fundamental knowledge of the underlying mechanisms of SLN-mediated gene delivery is conspicuously lacking, an imperative requirement in efforts aimed at further improving their efficiency. Here, we address recent advances in the use of SLNs as platform for delivery of nucleic acids as therapeutic agents. In addition, we will discuss available technology for conveniently producing SLNs. In particular, we will focus on underlying molecular mechanisms by which SLNs and nucleic acids assemble into complexes and how the nucleic acid cargo may be released intracellularly. In discussing underlying mechanisms, we will, when appropriate, refer to analogous studies carried out with systems based on cationic lipids and polymers, that have proven useful in the assessment of structure-function relationships. Finally, we will give suggestions for improving SLN-based gene delivery systems, by pointing to alternative methods for SLNplex assembly, focusing on the realization of a sustained nucleic acid release.
Keywords: Gene delivery; Solid lipid nanoparticles.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances.J Control Release. 2013 Feb 28;166(1):46-56. doi: 10.1016/j.jconrel.2012.12.014. Epub 2012 Dec 20. J Control Release. 2013. PMID: 23266451 Review.
-
Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells.Eur J Pharm Biopharm. 2008 Mar;68(3):545-54. doi: 10.1016/j.ejpb.2007.07.011. Epub 2007 Aug 8. Eur J Pharm Biopharm. 2008. PMID: 17881199
-
A new optimized formulation of cationic solid lipid nanoparticles intended for gene delivery: development, characterization and DNA binding efficiency of TCERG1 expression plasmid.Int J Pharm. 2014 Oct 1;473(1-2):270-9. doi: 10.1016/j.ijpharm.2014.06.022. Epub 2014 Jul 3. Int J Pharm. 2014. PMID: 24999055
-
Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid.Eur J Pharm Biopharm. 2007 Sep;67(2):320-8. doi: 10.1016/j.ejpb.2007.02.006. Epub 2007 Feb 14. Eur J Pharm Biopharm. 2007. PMID: 17368876
-
Solid lipid nanoparticles: promising therapeutic nanocarriers for drug delivery.Curr Drug Deliv. 2014;11(6):771-91. doi: 10.2174/156720181106141202122335. Curr Drug Deliv. 2014. PMID: 25469779 Review.
Cited by
-
RNA Combined with Nanoformulation to Advance Therapeutic Technologies.Pharmaceuticals (Basel). 2023 Nov 21;16(12):1634. doi: 10.3390/ph16121634. Pharmaceuticals (Basel). 2023. PMID: 38139761 Free PMC article. Review.
-
Comparative Analysis of the Physicochemical and Biological Characteristics of Freeze-Dried PEGylated Cationic Solid Lipid Nanoparticles.Pharmaceuticals (Basel). 2023 Nov 9;16(11):1583. doi: 10.3390/ph16111583. Pharmaceuticals (Basel). 2023. PMID: 38004448 Free PMC article.
-
Development and Characterization of Cationic Nanostructured Lipid Carriers as Drug Delivery Systems for miRNA-27a.Pharmaceuticals (Basel). 2023 Jul 14;16(7):1007. doi: 10.3390/ph16071007. Pharmaceuticals (Basel). 2023. PMID: 37513917 Free PMC article.
-
Intramuscular compatibility of an injectable anti-inflammatory nanodispersion from a standardized Bixa orellana oil (Chronic®): a toxicological study in Wistar rats.Inflammopharmacology. 2023 Apr;31(2):877-886. doi: 10.1007/s10787-023-01162-8. Epub 2023 Feb 28. Inflammopharmacology. 2023. PMID: 36853419
-
Advances in Lung Cancer Treatment Using Nanomedicines.ACS Omega. 2022 Dec 29;8(1):10-41. doi: 10.1021/acsomega.2c04078. eCollection 2023 Jan 10. ACS Omega. 2022. PMID: 36643475 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources